53
The Alpha Score is an informational signal based on public SEC fillings. It is not investment advice.
CEOJOURNAL SIGNAL SUMMARY·GENERATED FROM PUBLIC SEC FILINGS
P. Kent Hawryluk made an open-market purchase of Mbx Biosciences, Inc. on 2026-03-13, investing approximately $525,663. This is a CEOJournal signal summary placeholder — full narrative pending Claude Haiku enrichment.
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
Score Components
COMPOSITE ALPHA SCORE
53
Score calculated from open-market purchases only; 10b5-1 preplanned trades excluded; not investment advice.
OPPORTUNISM
Proxy from ownership-change magnitude. Real Opportunism signal will use %52W proximity once price data is in pipeline.
CONVICTION
Log-scaled from trade size. Real Conviction signal will use trade $ ÷ total compensation once DEF 14A data is in pipeline.
PATTERN
Placeholder — 90-day qualifying buy count requires historical Form 4 scrapes (Phase 2).
CLUSTER
Count of other insiders buying the same ticker in our current dataset window.
TRACK RECORD
Placeholder — executive tenure × prior buy P&L requires historical price tracking (Phase 2).
FORM 4 TRANSACTION HISTORYSOURCE: SEC EDGAR
| DATE | TRANSACTION TYPE | CODE | SHARES | PRICE | TOTAL VALUE | 10b5-1 | SCORE |
|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | Open-Market Purchase | P | 18,500 | $28.41 | $525,663 | N/A | 53 |
Data sourced from SEC EDGAR Form 4 filings, updated within 24 hours.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
EXECUTIVE PROFILE
P. Kent Hawryluk
Pres, CEO
P. Kent Hawryluk has served as President and Chief Executive Officer of MBX Biosciences, Inc. since its inception. He has extensive experience in the biotechnology industry, although specific prior roles or accomplishments are not detailed in the provided excerpt.
EDUCATION
Pending DEF 14A enrichment.
BOARD SEATS
Pending DEF 14A enrichment.
COMPENSATION & OWNERSHIP ·SOURCE: DEF 14A PROXY
ANNUAL BASE SALARY
$625,000
TOTAL COMPENSATION
$2,990,867
SHARES HELD
1,215,051
EST. HOLDINGS VALUE
$38.24M
as of May 30, 2026 close
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
RELATED SIGNALS